Pre-made Avizakimab biosimilar ( Whole mAb, anti-IL21 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-041
Anti-IL21 therapeutic antibody (Pre-made Avizakimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Avizakimab (formerly BOS 161721) is a fully human anti-interleukin 21 monoclonal antibody, being developed by Boston Pharmaceuticals, for treatment of autoimmune disorders including systemic lupus erythematosus.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL21 therapeutic antibody (Pre-made Avizakimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Systemic lupus erythematosus|
|Conditions Discontinued||Autoimmune disorders|